Analysis index

1 ml citrate plasma, frozen

70% – 120%

Children: please refer to findings report

• Evaluation of a reduced Quick’s value without oral anticoagulation
• Suspicion of hereditary factor–II–deficiency (rare, approximately 1:1.000.000
• Suspicion of acquired factor–II–deficiency (due to vitamin–K–deficiency or liver synthesis dysfunction)

Guide to interpretation:

50 % – 70 %: Largely sufficient for normal hemostasis

25 % – 50 %: Increased risk of bleeding. Minor operations with slight risk of bleeding are possible, no blind punctures. Physiological in newborns.

15 % – 25 %: Increased risk of bleeding, substitution therapy required prior to surgical procedures and in case of injuries.

< 10 %: Markedly increased risk of spontaneous bleeding, also life-threatening (i.e. brain hemorrhages)

When taking DOAKs (Dabigatran, Rivaroxaban, Apixaban or Edoxaban), an evaluation of the factor activity should be sought prior to taking the next dose.